bexagliflozin
Selected indexed studies
- Bexagliflozin: First Approval. (Drugs, 2023) [PMID:36867399]
- Bexagliflozin. (, 2006) [PMID:37748011]
- Bexagliflozin. (Clin Diabetes, 2024) [PMID:38230346]
_Worker-drafted node — pending editorial review._
Connections
bexagliflozin is a side effect of
Sources
- Bexagliflozin: First Approval. (2023) pubmed
- Bexagliflozin. (2006) pubmed
- Bexagliflozin. (2024) pubmed
- Safety and effectiveness of the sodium-glucose cotransporter inhibitor bexagliflozin in cats newly diagnosed with diabetes mellitus. (2023) pubmed
- Bexagliflozin for type 2 diabetes: an overview of the data. (2021) pubmed
- Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis. (2023) pubmed
- Bexagliflozin as an Adjunct Therapy to Diet and Exercise to Improve Glycaemic Control in Adults with Type 2 Diabetes. (2024) pubmed
- Novel FDA-approved bexagliflozin drug for treating type 2 diabetes mellitus. (2024) pubmed
- Bexagliflozin on Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (2025) pubmed
- SGLT2 inhibitor use in the management of feline diabetes mellitus. (2025) pubmed